-
The Hidden Clinical and Economic Costs of PPI Treatment Failures in Severe Erosive Esophagitis
Sep 9, 2025, 16:22 PM -
Explaining Psychiatric Comorbidities in Patients With Skin Conditions: The Importance of Clinical Characteristics and Patient-Reported Disease Impact
Sep 9, 2025, 16:22 PM -
Quantifying the Fiscal Benefits of Obesity Prevalence Reduction in China: A Public Economic Perspective
Sep 9, 2025, 16:22 PM -
From Pain to Patient Preferences Patient Engagement in Early HTA for Repurposing Losartan in Osteogenesis Imperfecta
Sep 9, 2025, 16:22 PM -
Review and Horizon Scanning of Advanced Therapy Medicinal Products in Slovenia: Registration, Reimbursement, and Future Pipeline
Sep 9, 2025, 16:22 PM -
The AI-Only Workflow: Model and Report Adaptation Without Human Setup
Sep 9, 2025, 16:22 PM -
How Cost-Effectiveness and Budget Impact Drive Pricing and Reimbursement: Insights From an International Comparative Study
Sep 9, 2025, 16:22 PM -
Efficacy and Safety of Inhaled Levofloxacin vs. Other Inhaled Antibiotics in the Treatment of Adults With Cystic Fibrosis and Chronic Pseudomonas Aeruginosa Lung Infection: An Updated Network Meta-Analysis
Sep 9, 2025, 16:22 PM -
Modeling Price Premiums of Oncology Drugs in Germany: A Cross-Validated Analysis Using XGBoost
Sep 9, 2025, 16:22 PM -
Cost Savings From Patient Preference-Based Allocation of High-Efficacy Therapies for MS: Evidence From Switzerland
Sep 9, 2025, 16:22 PM -
Pegunigalsidase Alfa Elfabrio® as a Long-Term Enzyme Replacement Therapy in Adults With Fabry Disease: A Systematic Literature Review
Sep 9, 2025, 16:22 PM -
Modeling the Future Clinical and Environmental Burden of Chronic Kidney Disease in Ghana and Uganda Between 2025 and 2030
Sep 9, 2025, 16:22 PM -
Equivalence of Measurement Properties of the Dermatology Life Quality Index (DLQI) Across 13 European Countries
Sep 9, 2025, 16:22 PM -
Inequity in Public Healthcare Utilization Among Persons With Disabilities in Bangladesh: A Benefit Incidence Analysis
Sep 9, 2025, 16:22 PM -
Organizational and Environmental Impact of Switching From Intravenous to Subcutaneous Immune Checkpoint Inhibitors (ICIs) in France: A Real-World Analysis Using PMSI Data
Sep 9, 2025, 16:22 PM -
Potential Impacts of Improvement in Turnaround Time
Sep 9, 2025, 16:22 PM -
HTA Submission Trends for EMA-Approved Oncology NASs Prior to the EU HTA Regulation 2018-2023
Sep 9, 2025, 16:22 PM -
AI-Driven Simulation of FDA DCOA Review to Inform Evidence Planning and Regulatory Strategy
Sep 9, 2025, 16:22 PM -
A Collection Of Essays on Patient Centricity in Intervention Development
Sep 9, 2025, 16:22 PM -
The Impact of Burosumab on the Clinical and Economic Burden of X-Linked Hypophosphatemia in Adult Patients in France
Sep 9, 2025, 16:22 PM
